NewAmsterdam Pharma (NASDAQ:NAMS) CAO Louise Frederika Kooij Sells 43,872 Shares

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) CAO Louise Frederika Kooij sold 43,872 shares of the company’s stock in a transaction on Friday, December 26th. The stock was sold at an average price of $35.30, for a total transaction of $1,548,681.60. Following the sale, the chief accounting officer directly owned 15,000 shares of the company’s stock, valued at approximately $529,500. This trade represents a 74.52% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Louise Frederika Kooij also recently made the following trade(s):

• On Tuesday, December 23rd, Louise Frederika Kooij sold 75,117 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $36.21, for a total value of $2,719,986.57.
• On Wednesday, December 24th, Louise Frederika Kooij sold 26,011 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $35.68, for a total value of $928,072.48.

NewAmsterdam Pharma Stock Performance

NAMS stock opened at $35.02 on Tuesday. The firm has a market cap of $3.97 billion, a P/E ratio of -17.08 and a beta of 0.05. NewAmsterdam Pharma Company N.V. has a 1 year low of $14.06 and a 1 year high of $42.00. The stock has a 50-day simple moving average of $37.03 and a 200-day simple moving average of $29.13.

NewAmsterdam Pharma (NASDAQ:NAMS) last released its quarterly earnings results on Wednesday, November 5th. The company reported ($0.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.03). The company had revenue of $0.35 million during the quarter, compared to analysts’ expectations of $4.54 million. NewAmsterdam Pharma had a negative return on equity of 28.30% and a negative net margin of 627.59%. On average, equities research analysts predict that NewAmsterdam Pharma Company N.V. will post -1.75 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts recently commented on the company. Needham & Company LLC increased their price target on NewAmsterdam Pharma from $40.00 to $46.00 and gave the company a “buy” rating in a report on Wednesday, November 5th. Citigroup increased their price objective on shares of NewAmsterdam Pharma from $42.00 to $50.00 and gave the stock a “buy” rating in a research note on Friday, October 17th. Weiss Ratings reissued a “sell (d-)” rating on shares of NewAmsterdam Pharma in a report on Wednesday, October 8th. Stifel Nicolaus increased their price objective on NewAmsterdam Pharma from $44.00 to $50.00 and gave the stock a “buy” rating in a report on Tuesday, December 16th. Finally, Royal Bank Of Canada raised their target price on shares of NewAmsterdam Pharma from $39.00 to $44.00 and gave the company an “outperform” rating in a research note on Thursday, November 6th. Eight equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $45.90.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Capital World Investors boosted its stake in shares of NewAmsterdam Pharma by 17.1% during the 3rd quarter. Capital World Investors now owns 9,822,711 shares of the company’s stock worth $279,358,000 after acquiring an additional 1,434,986 shares in the last quarter. RA Capital Management L.P. raised its position in shares of NewAmsterdam Pharma by 14.6% during the first quarter. RA Capital Management L.P. now owns 10,138,938 shares of the company’s stock worth $207,544,000 after purchasing an additional 1,293,938 shares during the period. Jennison Associates LLC lifted its holdings in shares of NewAmsterdam Pharma by 42.5% during the third quarter. Jennison Associates LLC now owns 4,198,554 shares of the company’s stock valued at $119,407,000 after purchasing an additional 1,252,451 shares during the last quarter. Duquesne Family Office LLC boosted its position in shares of NewAmsterdam Pharma by 131.2% in the 3rd quarter. Duquesne Family Office LLC now owns 1,923,700 shares of the company’s stock valued at $54,710,000 after purchasing an additional 1,091,525 shares during the period. Finally, Adage Capital Partners GP L.L.C. increased its stake in NewAmsterdam Pharma by 54.5% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 3,013,009 shares of the company’s stock worth $54,566,000 after purchasing an additional 1,062,359 shares in the last quarter. Institutional investors own 89.89% of the company’s stock.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.